Nkarta, Inc. (NASDAQ:NKTX) Insider David Shook Sells 8,638 Shares

Nkarta, Inc. (NASDAQ:NKTX) insider David Shook sold 8,638 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $19,003.60. Following the completion of the sale, the insider now directly owns 190,955 shares in the company, valued at approximately $420,101. The trade was a 4.33 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Nkarta Stock Performance

NKTX stock opened at $2.47 on Friday. The business has a fifty day simple moving average of $2.54 and a 200-day simple moving average of $4.21. Nkarta, Inc. has a 52 week low of $2.08 and a 52 week high of $16.24.

Institutional Investors Weigh In On Nkarta

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Erste Asset Management GmbH acquired a new position in shares of Nkarta in the 3rd quarter valued at about $33,000. GAMMA Investing LLC raised its holdings in Nkarta by 110.9% in the third quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock valued at $45,000 after buying an additional 5,243 shares during the period. Forefront Analytics LLC purchased a new position in Nkarta in the second quarter valued at approximately $70,000. Intech Investment Management LLC acquired a new position in Nkarta during the third quarter valued at approximately $74,000. Finally, SG Americas Securities LLC purchased a new stake in Nkarta during the third quarter worth approximately $93,000. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NKTX has been the topic of several analyst reports. Rodman & Renshaw started coverage on shares of Nkarta in a research note on Wednesday, October 9th. They set a “buy” rating and a $14.00 price target on the stock. Needham & Company LLC lowered their target price on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 8th. RODMAN&RENSHAW raised Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. HC Wainwright decreased their price objective on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Finally, Mizuho dropped their target price on Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Nkarta presently has a consensus rating of “Buy” and an average price target of $15.00.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.